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AbstrACt
Objectives To assess biostatistical quality of study 
protocols submitted to German medical ethics committees 
according to personal appraisal of their statistical 
members.
Design We conducted a web- based survey among 
biostatisticians who have been active as members in 
German medical ethics committees during the past 3 
years.
setting The study population was identified by a 
comprehensive web search on websites of German 
medical ethics committees.
Participants The final list comprised 86 eligible persons. 
In total, 57 (66%) completed the survey.
Questionnaire The first item checked whether the 
inclusion criterion was met. The last item assessed 
satisfaction with the survey. Four items aimed to 
characterise the medical ethics committee in terms 
of type and location, one item asked for the urgency 
of biostatistical training addressed to the medical 
investigators. The main 2×12 items reported an individual 
assessment of the quality of biostatistical aspects in the 
submitted study protocols, while distinguishing studies 
according to the German Medicines Act (AMG)/German Act 
on Medical Devices (MPG) and studies non- regulated by 
these laws.
Primary and secondary outcome measures The 
individual assessment of the quality of biostatistical 
aspects corresponds to the primary objective. Thus, 
participants were asked to complete the sentence ‘In x% 
of the submitted study protocols, the following problem 
occurs’, where 12 different statistical problems were 
formulated. All other items assess secondary endpoints.
results For all biostatistical aspects, 45 of 49 (91.8%) 
participants judged the quality of AMG/MPG study 
protocols much better than that of ‘non- regulated’ studies. 
The latter are in median affected 20%–60% more often 
by statistical problems. The highest need for training was 
reported for sample size calculation, missing values and 
multiple comparison procedures.
Conclusions Biostatisticians being active in German 
medical ethics committees classify the biostatistical quality 
of study protocols as low for ‘non- regulated’ studies, 
whereas quality is much better for AMG/MPG studies.
IntrODuCtIOn
Problem formulation
Medical ethics committees (institutional 
review boards) aim to judge the quality and 
validity of medical studies in order to ensure 
an ethically justifiable positive benefit–risk 
profile.1–3 Their members do not only assess 
the submitted material but also act as consul-
tants. Besides medical content, the board 
verifies legal and scientific validity including 
biostatistical aspects of the study design 
and analysis strategy.4–6 Although general 
strengths and limitations of this study
 ► This is the first survey among biostatisticians active 
in German medical ethics committees to assess the 
individual assessment of the quality of and the com-
pleteness of information on biostatistical aspects in 
the submitted study protocols.
 ► Although having put much effort in searching for 
all biostatisticians active in German medical ethics 
committees, the target population was not com-
pletely identified.
 ► Confidentiality issues did not allow direct and ob-
jective assessment of individual study protocols’ 
content.
 ► This survey classified study protocols as regulat-
ed by the German Medicines Act/German Act on 
Medical Devices and those non- regulated by these 
laws, where the latter covers a very heterogeneous 
group of studies for which the statistical require-
ments are not all the same.
 ► This survey was conducted too early to study the im-
pact on recent revisions on the statistical concepts 
of estimands.
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guidance for a good biostatistical practice in medical 
research projects exists, there is no consensus and only 
limited guidance to what extent medical ethics commit-
tees should assess these statistical aspects.5–8 According 
to the last revision of the German Drug Regulation Law 
in 2016 (Bundesgesetzblatt, § 41a), a biostatistician is 
a mandatory member of a medical ethics committee, 
next to medical as well as legal experts, and lay persons.9 
However, not all medical ethics committees appraise 
legally regulated studies in which case a biostatistician is 
not mandatory.10–13 Moreover, medical research is faced 
with the new challenges related to the digitalisation of the 
health system and the focus on personalised medicine, 
which also brings along new tasks and perspectives for 
medical ethics committees.14
Purpose or research question
To increase the biostatistical quality of study protocols, 
standards for biostatistical reporting and for biostatistical 
reviewer comments have to be implemented in Germany 
that account for the fact that the organisation and compo-
sition of German medical ethics committee organisation 
are quite heterogeneous. Of course, on the long- run 
international standard have to be agreed on. To achieve 
this global aim, the first step is to assess the current level 
of statistical quality of submitted study proposals, so that 
gaps and challenges can be identified.
For this purpose, we conducted a comprehensive 
survey among biostatisticians who were active in German 
medical ethics committees between 2016 and 2018. The 
aim was to evaluate and quantify the personal assessment 
of the participants of the quality and completeness of 
statistical aspects in clinical study protocols submitted to 
German medical ethics committees.
A direct judgement of the statistical quality of study 
protocols would have required the assessment of rele-
vant protocol extracts or even entire study protocols 
by the experts. This was, however, not possible due to 
enforced data protection mechanisms. Many medical 
ethics committees argued that original protocols (even 
partly and anonymised) could not be made available 
for the planned assessment without impairing the trust 
which is an essential part of the medical ethics commit-
tee’s standing.
To overcome this problem, we decided to ask biostat-
isticians in medical ethics committees to give a global, 
personal assessment on specific issues of the statistical 
quality and completeness of study protocols. On the one 
hand, the individual impression does not objectively 
reflect the ‘true’ quality. On the other hand, objective 
quality criteria are very hard to define and would defin-
itively impose a need for a controversial discussion. 
Therefore, the individual global quality assessment of 
biostatisticians in medical ethics committees provides 
an informative marker to at least roughly assess current 
standards and problems. Biostatisticians in medical 
ethics committees review many study protocols and can 
well reflect the statistical problems currently met. From 
these findings, we can identify statistical topics which 
need an enforced focus, for example, within the frame-
work of Good Clinical Practice courses, specific training 
addressed to the statistical reviewers to improve clarity 
of statistical reviewer comments and other training 
addressed to the medical investigators to improve their 
statistical knowledge.15–17
MethODs
Qualitative approach and research paradigm
This study is a comprehensive systematic survey among 
biostatisticians who were members of German medical 
ethics committees between 2016 and 2018.
researcher characteristics and reflexivity
The questionnaire was developed by a senior biostatisti-
cian, reviewed and extended by five independent biostat-
isticians including two professors of biostatistics, two 
senior biostatisticians and one bachelor student with a 
limited background in biostatistics. The latter person was 
consulted in particular to assess the comprehensibility of 
the wording.
Context
All authors, who developed the survey, analysed the data 
and wrote this article, are members of the joint project 
group ‘Biometry in ethics committees’ of the German 
Association for Medical Informatics, Biometry and Epide-
miology (GMDS) e. V. and the German Region of the 
International Biometric Society (https:// gmds. de/ aktiv-
itaeten/ medizinische- biometrie/ arbeitsgruppenseiten/ 
projektgruppen/ biometrie- in- der- ethikkommission/, 
accessed September 2019). This group was founded in 
2017 and aims to strengthen the work of biostatisticians in 
medical ethics committees by offering specific training (in 
methods as well as communication of statistical issues to 
non- statisticians), establishing a communication network 
for mutual support and developing specific guidelines, 
which allow a standardised, high- quality statistical review 
of study protocols.
Data collection instruments and technologies
The questionnaire was implemented as an online survey ( 
www. umfrageonline. com, accessed September 2019). The 
survey consisted of 31 items, which were grouped in 11 
steps/pages in the online survey. Questions were formu-
lated in German. The original survey can be found here 
(https://www. umfrageonline. com/ s/ 6b2e8f4& preview= 
1& DO- NOT- SEND- THIS- LINK- ITS- ONLY- PREVIEW, 
accessed September 2019). English translations are 
provided in online supplementary appendix 1.
The first item checked the key inclusion criterion if 
the respondent served as statistical expert in a medical 
ethics committee within the last 3 years. Only persons who 
answered this question positively were included in the 
final analysis. The last item evaluated if the respondent 
enjoyed the survey. Of the remaining 29 main items, 4 
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items characterised specific features of the medical ethics 
committee and the review process within the medical 
ethics committee. We asked (1) for the type of the 
medical ethics committee (ethics committee of a medical 
faculty, of a State Chamber of Physicians (Landesärzteka-
mmer) or other), (2) for the federal state in Germany, 
where the medical ethics committee is located, (3) how 
many studies the respondent reviews on average per year 
(in steps of 50) and (4) if the respondent is exclusively 
responsible for study proposals according to the German 
Medicines Act (AMG)/German Act on Medical Devices 
(MPG) or also for studies that are non- regulated by these 
laws which will be referred to in the following briefly as 
'non- regulated studies'. In case the respondent’s medical 
ethics committee is responsible for regulated as well as 
for non- regulated studies, another (conditional) item 
asked whether the statistical quality of study protocols is 
better in the regulated compared with the non- regulated 
setting.
Additionally, 2×12 items asked for assessing the 
completeness and correctness of different biostatistical 
aspects (12 for the regulated setting, 12 for the non- 
regulated setting conditional on the responsibilities of 
the specific medical ethics committee as marked in the 
previous item). Participants were asked to complete the 
sentence ‘In x% of the submitted study protocols, the 
following problem occurs’, were 12 statistical problems 
were addressed (eg, ‘specification of the significance 
level is missing’). Participants could provide percentages 
in steps of 10% (0%–100%) with a higher percentage 
indicating a worse result. In principle, items formulated 
in the way ‘In x% of the submitted study protocols, the 
following problem occurs’ could have also been assessed 
on an interval scale by allowing for continuous specifica-
tions of percentages. This would have pretended a quan-
titative and objective assessment. However, the subjective 
impression is surely neither quantitative nor completely 
objective.
An additional item asked for the need to refresh the 
statistical knowledge of the, medical or epidemiological 
investigator on a certain topic to be selected out of a list 
of 9 statistical topics with the option to add additional 
ones. In addition, this need had to be assessed as low, 
medium or high.
Data processing
The online survey system saved the answers of the partic-
ipants in a central database where data can be down-
loaded in various formats. An extended group of experts 
including the authors validated the online survey by 
testing and commenting it. Final corrections were inte-
grated after the validation phase.
units of study
The study population is defined as all biostatisticians 
being members of a German medical ethics committee 
between 2016 and 2018.
sampling strategy
To identify the study population, a web search on the 
homepages of all German medical ethics committees was 
performed which resulted in a preliminary email list. All 
these email addresses were freely available on the web. 
Moreover, several persons known to be active in ethics 
committees were asked to complete this list in agreement 
with the specific biostatistician. The final list of eligible 
candidates consisted of 86 biostatisticians.
Data collection methods
The call to participate in the survey was sent out by email 
on 28 November 2018 with a reminder on 13 December 
2018. The survey was opened until 15 December 2018. 
Some participants actively asked for the possibility to 
slightly extend the deadline on which we agreed. The orig-
inal survey was, however, open only between 1 December 
2018 and 31 January 2019, so that after that time period 
data collection was completed.
techniques to enhance trustworthiness
The webpage for the survey was not publicly published to 
avoid participation of persons not belonging to the study 
population. Still, in principle, anyone who was aware of 
the link could have participated in the survey. There is 
no way to check for fulfilment of the inclusion criterion 
or correctness of the provided answers. However, as the 
link was not easily available and the study population was 
likely to be highly compliant, this risk seems to be minor. 
The survey could be completed only once from a single IP 
address. In principle, participants could have completed 
the survey several times using different IP addresses, which 
seems very unlikely. As the survey was anonymous due to 
data protection reasons, it is impossible to verify such 
fraud. However, as there was no benefit in completing the 
survey more than once, this risk seems to be minor. We 
did not advertise the survey by means of global mailing 
lists within biostatistical societies, although this approach 
was discussed. A limited and focused mailing list is pref-
erable as otherwise no responders’ proportion could 
have been evaluated which is a crucial quality indicator 
of a survey. Moreover, a global mailing list would have 
included a large proportion of recipients who did not 
fulfil the eligibility criteria.
ethical issues pertaining to human subjects
The online survey was anonymised and most items 
included an option for providing no answer. The question 
asking for the medical ethics committee’s federal state 
allowed for a potential reidentification of the respondent 
in case of a small federal state like Bremen. Respondents 
were therefore free to leave this box blank. No personal 
data were collected from the participants. Participation 
in the survey was voluntary and not rewarded. To enable 
reproduction of the results presented in this paper, the 
final dataset is freely available from the Dryad reposi-
tory (https:// datadryad. org/ stash/ share/ Vjof DJko UtqI 
jjaJ Q84O 7FB1 W5cJ u78g 04cN ey044no), without any 
 o
n
 June 3, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032864 on 4 February 2020. Downloaded from 
4 Rauch G, et al. BMJ Open 2020;10:e032864. doi:10.1136/bmjopen-2019-032864
Open access 
Table 1 Characteristics of the medical ethics committees 
to which the participants are appointed
Item 2: In which type of ethics committee 
have you been active?*
n=57 (%)
Medical ethics committee of a medical faculty 
of a university
46 (80.7)
Medical ethics committee of a State Chamber 
of Physicians (Landesärztekammer)
15 (26.3)
Others 7 (12.3)
Item 3: Which German federal state is the 
medical ethics committees located to which 
you were affiliated?*
n=50 (%)
Baden- Württemberg 7 (14.3)
Bavaria 4 (8.2)
Berlin 3 (6.1)
Brandenburg 0 (0.0)
Bremen 0 (0.0)
Hamburg 1 (2.0)
Hesse 3 (6.1)
Mecklenburg Western Pomerania 0 (0.0)
Lower Saxony 6 (12.2)
Northrhine- Westphalia 14 (28.6)
Rhineland Palatinate 2 (4.1)
Saarland 0 (0.0)
Saxony 1 (2.0)
Saxony- Anhalt 4 (8.2)
Schleswig- Holstein 3 (6.1)
Thuringia 2 (2.0)
Item 4: How many study proposals 
(amendments and annual reports excluded) 
do you review on average per year?
n=56 (%)
Up to 50 18 (32.1)
51–100 14 (25.0)
101–150 7 (12.5)
151–200 7 (12.5)
>200 10 (17.9)
Item 5: Which kinds of studies do you review 
as member of a medical ethics committee?*
n=56 (%)
Studies regulated by AMG or MPG 3 (5.4)
Studies in a non- regulated setting 3 (5.4)
Both 50 (89.3)
*Multiple responses possible (in case of membership in several 
ethics committees).
AMG/MPG, German Medicines Act/German Act on Medical 
Devices.
information on the medical ethics committee’s federal 
state to avoid any risk of potential reidentification. No 
ethical approval was necessary for this voluntary survey in 
healthy participants without any risk of putting harm to 
the respondents and without any direct medical research 
focus.
Data analysis
This is an exploratory study, which is analysed using 
descriptive statistical methods. Items 1–6 as well as 
items 30 and 31 are simple categorical items assessed 
on a multiple- choice basis. The items were evaluated by 
means of absolute and relative frequencies. The 2×12 
items asking for the assessment of the completeness and 
correctness of different biostatistical aspects are Likert- 
scaled ordinal variables with 11 possible outcomes (0%, 
10%, …, 100%). For these items, we reported absolute 
and relative frequencies and graphically displayed them 
as stacked bar charts. Moreover, we provided medians, 
quartiles and grouped boxplots, where two groups of 
studies are considered (regulated vs non- regulated 
studies). All analyses were performed using the statistical 
software R, V.3.5.1. The original dataset (excluding infor-
mation on the specific German federal state) is freely 
available from the Dryad repository (https:// datadryad. 
org/ stash/ share/ Vjof DJko UtqI jjaJ Q84O 7FB1 W5cJ u78g 
04cN ey044no) to allow for reproducibility.
Patient and public involvement
This survey does not include patients or the general 
public. The design and the development of the survey was 
intensively discussed by the members of the joint project 
group ‘Biometry in ethics committees’ of the GMDS e. V. 
and the German Region of the International Biometric 
Society.
results
Table 1 shows the characteristics of the medical ethics 
committees to which the 57 participants of the survey are 
appointed. Note that the number of answers differ per 
item, as the online survey offered the option to abstain 
from answering a specific question. A majority of 46 partic-
ipants (80.7%) were members of an ethics committees of 
a medical faculty of a university, whereas 15 (26.3%) were 
members of an ethics committee of a State Chamber of 
Physicians (Landesärztekammer). Some participants were 
members of more than one medical ethics committee at 
the same time.
A total of 47 participants answered the question on 
the location of the medical ethics committee to which 
they were appointed as member. The medical ethics 
committees are located in 12 out of 16 German federal 
states, where 14 (28.6%) participants were members of 
medical ethics committees in Northrhine- Westphalia and 
7 (14.3%) in Baden- Württemberg.
A total of 18 (32.1%) participants reviewed up to 
50 study proposals per year, 14 participants (25.0%) 
reviewed between 51 and 100 study proposals per year 
and 24 participants (42.0%) reviewed more than 100 
study proposals on average per year.
The vast majority of 50 participants (89%) reviewed 
both—study proposals according to AMG/MPG and 
study proposals in a non- regulated setting.
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Table 2 General biostatistical quality of study proposals
Item 6: Do you in general have the impression 
that the biostatistical quality of ethical 
proposals for studies regulated by AMG/MPG 
differs compared with proposals in a non- 
regulated setting?
n=47 (%)
Yes, ethical proposals for studies regulated by 
AMG/MPG have a higher biostatistical quality on 
average
45 (91.8)
Yes, ethical proposals for studies in a non- 
regulated setting have a higher biostatistical 
quality on average
0 (0.0)
No, the biostatistical quality does not differ on 
average
2 (4.1)
Item 11: How do you consider the need for 
additional training in the following biostatistical 
areas for investigators submitting protocols to 
medical ethics committees?
n=45 (%)
Study design   
  Low 7 (15.6)
  Middle 23 (51.1)
  High 15 (33.3)
Wording of the study aims, hypotheses and/or endpoints
  Low 1 (2.2)
  Middle 22 (48.9)
  High 22 (48.9)
Sample size calculation   
  Low 2 (4.4)
  Middle 15 (33.3)
  High 27 (60.00)
  Not assessable 1 (2.2)
Differentiation between confirmatory and exploratory analyses
  Low 4 (8.9)
  Middle 17 (37.8)
  High 24 (53.3)
Handling of missing values   
  Low 2 (4.4)
  Middle 9 (20.00)
  High 34 (75.6)
Description of the statistical analysis   
  Low 1 (2.3)
  Middle 23 (52.3)
  High 20 (45.5)
Multiple comparisons problems   
  Low 3 (6.7)
  Middle 16 (35.6)
  High 26 (57.8)
Adjustment for covariables   
  Low 3 (6.7)
  Middle 18 (40.0)
  High 24 (53.3)
Continued
With respect to the general biostatistical quality of study 
protocols, table 2 displays the results of items 6 and 11. 
Only 47 participants answered Item 6, assessing if the 
statistical quality of ethical proposals generally differs 
between regulated and the non- regulated studies. As this 
item was placed in the survey before the specific biostatis-
tical aspects were named, this general formulation seemed 
to be difficult to understand for a large part of the partic-
ipants. Out of 47 participants in total who responded to 
item 6, a majority of 45 (95.7%) stated that study proto-
cols under regulatory requirements (AMG/MPG) are 
on average of higher statistical quality compared with 
studies without such requirements. The remaining 2 
(4.3%) participants stated that there is no difference on 
average. Item 11 asked how the participants considered 
the need for additional training in different statistical 
areas addressed to the investigators submitting protocols 
(see table 2). A high need for a training was especially 
identified for ‘handling of missing values’ as indicated 
by 34 participants (75.6%), for ‘sample size calculation’ 
as indicated by 27 participants (60.0%), for ‘multiple 
comparison procedures’ 26 (57.8%) and for ‘adjustment 
for covariables’ 26 (57.8%). For all topics, at least 70% 
of participants considered the need for a refreshment of 
statistical knowledge as middle or high.
Items 7–10 asked to assess completeness and correct-
ness of biostatistical aspects while distinguishing studies 
according to the regulatory setting (AMG, MPG) (items 7 
and 8) and studies without regulatory requirements (items 
9 and 10). Participants were only able to judge those study 
types (regulated and/or non- regulated) that were spec-
ified in item 5. Participants were asked to complete the 
sentence ‘In x% of the submitted study protocols, the 
following problem occurs’, where 12 statistical problems 
were formulated (eg, ‘specification of the significance 
level is missing’). Participants could give the percentage 
in steps of 10% (0%–100%) with a higher percentage indi-
cating a worse result. Note that, study protocols submitted 
to German ethics committees can cover various types of 
research including observational studies, retrospective 
analyses and surveys. Not all of the 12 aspects formulated 
below are applicable to all types of studies. The requested 
percentages refer to the average of all studies, which have 
been reviewed by the participant. However, there also was 
the option to classify a specific aspect as ‘not assessable’. 
As a consequence, the number of valid responses varies 
per item, where lower values might indicate items that 
are more difficult to judge. Moreover, some participants 
interrupted the survey after the assessment of some items, 
probably because the statistical problems are repeated for 
regulated and non- regulated studies, which might have 
decreased the motivation. The results referring to the 
valid responses are presented in table 3 and displayed 
in figure 1 as grouped boxplots. Additionally, figure 2 
displays the percentages of the item categories for both 
study types as stacked bar plots.
It turns out that protocols of non- regulated studies tend 
to be of much lower statistical quality and show a lower 
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Randomisation/stratification   
  Low 10 (22.2)
  Middle 27 (60.00)
  High 6 (13.3)
  Not assessable 2 (4.4)
Additional aspects (added as free- text response by the 
participants)
  Data management   
  Regulatory view   
  Testing versus estimating   
AMG/MPG, German Medicines Act/German Act on Medical 
Devices.
Table 2 Continued
Table 3 Medians and quartiles of percentages of assessments for completeness and correctness of statistical aspects for 
AMG studies in comparison to non- regulated studies (higher values indicate a lower level of completeness and/or correctness)
In x(%) of the ethical proposals
Median (1.; 3. quartile), n=number of valid responses 
(excluding ‘non assessable’)
Regulated studies (AMG, MPG) Non- regulated studies
(1)… wording of study aims, hypotheses and/or endpoints are 
inadequate or inconsistent.
10 (10; 20), n=45 50 (20; 80), n=45
(2)… specification of the significance level is missing. 10 (0; 10), n=44 30 (10; 50), n=45
(3)… sample size calculation is incomplete, inadequate or 
missing completely.
20 (10; 30), n=45 70 (50; 80), n=45
(4)… only general statements on statistical analysis methods are 
provided not fitting and addressing the specific study aim.
10 (10; 25), n=46 70 (50; 80), n=45
(5)… no clear differentiation between confirmatory and 
explanatory analyses is provided.
15 (10; 27.5), n=46 70 (50; 82.5), n=45
(6)… specification of one- sided or two- sided statistical testing 
is missing.
10 (10; 30), n=44 55 (30; 87.5), n=43
(7)… description of how to handle missing values is incomplete, 
inadequate or missing completely.
40 (22.5; 70), n=46 90 (80; 90), n=42
(8)… description of how to handle multiple comparisons 
problems is incomplete, inadequate or missing completely.
30 (20; 50), n=45 80 (70; 90), n=42
(9)… description of how and for which covariables adjustment is 
planned is incomplete, inadequate or missing completely.
25 (20; 50), n=46 80 (50; 90), n=42
(10)… specification of randomisation and stratification is 
incomplete, inadequate or missing completely.
10 (10; 30), n=45 65 (50; 80), n=36
(11)… no study biometrician is specified. 20 (10; 50), n=43 70 (40; 90), n=40
(12)… description of statistical methods is not sufficiently 
specified.
20 (10; 40), n=45 80 (60; 90), n=42
AMG/MPG, German Medicines Act/German Act on Medical Devices.
level of completeness, regardless of the specific topic. 
Differences in medians of the ratings between regulated 
and non- regulated studies range between 20% and 60%. 
The statistical aspects ‘missing values’, ‘multiple compar-
ison problems’ as well as ‘adjustment for covariables’ 
show the highest discrepancies between both study types. 
For instance, the statistical methods are not sufficiently 
specified in 80% on average (median) for non- regulated 
study proposals whereas this is the case in only 20% on 
average (median) for studies with regulatory require-
ments. Similarly, for non- regulated studies only general 
statements on statistical analysis methods are provided 
not fitting and addressing the specific study aim in 70% 
on average (median), whereas this is only stated in 10% 
on average (median) for regulated studies. For non- 
regulated studies, all 12 statistical aspects show high 
deficiencies, while only in 10% on average (median) of 
all proposals of regulated studies aspects are mentioned 
which have not been completely or correctly addressed in 
the proposals.
DIsCussIOn
This systematic survey among biostatisticians serving in 
German medical ethics committees aimed to assess the 
individual impression of completeness and correctness 
of biostatistical aspects of submitted study protocols. As 
an overall result, the completeness and correctness of 
handling statistical issues in the submitted study proto-
cols is heterogeneous. There is a notably difference in 
quality between study protocols with and without regula-
tory requirements, where the latter show major deficits. 
A specifically high need for refreshment was identified 
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Figure 1 Grouped boxplots for completeness and correctness of 12 biostatistical aspects for regulated and non- regulated 
studies. AMG/MPG, German Medicines Act/German Act on Medical Devices.
for ‘handling of missing values’, ‘sample size calcula-
tion’, ‘multiple comparison procedures’ and ‘adjustment 
for covariables’. However, there also exist quite general 
deficiencies for non- regulated studies, as the descrip-
tion of the statistical methods is not sufficiently speci-
fied. It should be mentioned that for regulatory studies 
the International Conference on Harmonization (ICH) 
E9 guideline offers guidance on how to analyse a clin-
ical study.6 This guideline is also helpful for the non- 
regulated settings but may be unknown to members of 
this community.13
To the best of our knowledge, this is the first survey 
among biostatisticians who were members of German 
medical ethics committees and the first attempt to assess 
the quality and completeness of biostatistical issues in 
medical study protocols. Wang et al conducted a survey 
among biostatistical consultants with respect to the quality 
of reporting the statistical analysis strategy after data was 
already analysed.18 The four most frequently reported 
statistical problems were ‘removing or altering some 
data records to better support the research hypothesis’, 
‘interpreting the statistical findings on the basis of expec-
tation, not actual results’, ‘not reporting the presence of 
key missing data that might bias the results’ and ‘ignoring 
violations of assumptions that would change results from 
positive to negative’. Clark et al screened original study 
protocols submitted to UK ethics committees for the 
completeness and correctness of sample size derivation.19 
They found that only 42% of the study protocols reported 
all information, which is required to accurately repro-
duce the sample size. Kilkenny et al conducted a survey 
of the quality of experimental design, statistical analysis 
and reporting of research in animal studies.20 They found 
that only 59% of the studies stated the hypothesis or 
objective of the study and the number and characteris-
tics of the animals used und only 70% of the publications 
described their methods and presented the results with 
a measure of error or variability.20 These findings are in 
line with the results of our survey. In addition, Hall et al 
looked at the methodological quality of surgical clinical 
trials.21 They reported that less than 50% of the studies 
commented on potential bias in the assessment of the 
outcome, adequately described the randomisation tech-
nique, or commented on sample size calculation.21 Peng 
et al conducted a review on published epidemiological 
papers to assess the reproducibility of epidemiological 
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Figure 2 Stacked bar plots for completeness and correctness of 12 biostatistical aspects differing between regulated and 
non- regulated studies. AMG/MPG, German Medicines Act/German Act on Medical Devices.
research.22 They found that 30% of the publications did 
not report the implementation of the statistical analysis. 
Begley et al commented that there is a general problem 
of reproducibility of study results, in particular in preclin-
ical studies.23 This goes in line with the problems of study 
protocols and designs reported by Ioannidis et al.17
A total of 57 (66%) of the contacted 86 persons partic-
ipated and fulfilled the inclusion criteria. This corre-
sponds to a high participation proportion. However, it 
remains unknown whether all potential participants were 
truly identified and contacted.
A further limitation of our survey is that it does not 
provide an overview of the objectively measured quality 
and completeness of biostatistical aspects of study proto-
cols but that it only refers to the subjective, individual 
impression of the statistical members of the ethics 
committees. An objective rating of the study protocols, 
however, was not possible due to data and privacy protec-
tion issues, as this would have required screening of the 
submitted study documents. Moreover, objective quality 
measures are difficult to define, because as the meaning 
of ‘adequate’ quality might differ considerably. The 
subjective ratings of completeness and correctness are 
subject to interrater and intrarater variability. Therefore, 
the results should rather be interpreted as a rough indica-
tion and not as definite numbers.
As a third limitation, we consider the fact that the survey 
could not assess recent issues added in an addendum to 
the ICH E9 guideline.24 It presents a structured frame-
work to link trial objectives to a suitable trial design and 
tools for estimation and hypothesis testing. This frame-
work introduces the concept of an estimand, translating 
the trial objective into a precise definition of the treat-
ment effect that is to be estimated. It also aims to facili-
tate the dialogue between disciplines involved in a clinical 
trial.
Even in view of these limitations, the survey clearly 
indicates the need for basic and advanced statistical train-
ings and guidance for medical researchers. All medical 
faculties in Germany have established biostatistical 
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units providing consulting services. However, this does 
not seem to be sufficient to enable medical researchers 
to develop protocols, which cover statistical issues 
adequately. Reasons could be that medical researchers 
undervalue the impact of an appropriate biometrical 
planning on the quality and validity of medical studies. 
In personal discussions with participants of this survey, 
several of them reported frequent examples where the 
statistical analysis strategy in study protocols is addressed 
with a single general sentence like ‘The data are analysed 
with valid statistical methods.’ This does not only indicate 
a lack of statistical knowledge but also a lack of awareness 
that statistical methods have an important impact on the 
validity of medical research.
The survey also gauges the range of methodological 
challenges encountered by biostatisticians being member 
of a medical ethics committee. Often a biostatistician is 
the last methodological sentinel before a study is imple-
mented in a clinical setting. In order to involve more 
biostatisticians in medical ethics committees, there is a 
need to provide support to enable them to adequately 
discharge their responsibilities. Unfortunately, the survey 
did not check how the remaining members react on revi-
sion requests by biostatisticians and if these requests are 
adequately addressed before the final vote of the medical 
ethics committee on the criticised study protocol. More-
over, we did not formally assess if biostatisticians, who 
are members of medical ethics committees, formulate 
their requests in comparable detail and persistence. 
Due to own experiences and based on narrative reports, 
we suspect that biostatistical concerns cannot be easily 
communicated to and understood by the non- statistical 
members of the medical ethics committee. Thus, there is 
a need to establish a better communication, which allows 
expressing biostatistical concerns in a convincing easily 
understandable language.
It is, therefore, time to communicate the general impor-
tance of statistics for medical research. This includes the 
establishment of guidelines for protocol writing and 
templates like the SPIRIT Statement, which also handles 
statistical input to a protocol.25 26 Furthermore, the imple-
mentation of reporting guidelines like STROBE should 
be made more popular.27 Moreover, the development of 
specific trainings and guidance on how to address specific 
statistical challenges is required. Finally, national stan-
dards for the tasks of a biostatistician as a member of a 
medical ethics committee must be formulated.28 29
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